Initial sampling Sample Clauses

Initial sampling. As proof that the Supplier is capable of fulfilling product requirements in the necessary quantity and quality the Supplier must conduct a performance test after consultation with the Customer (capacity study, verification of process capability) under conditions similar to series production as well as a statistical evaluation of the data. Before series production begins, the Supplier must provide the agreed quantity of initial samples produced under conditions similar to series production and these must be released by the Customer. The initial sampling procedure must be conducted in accordance with VDA volume 2 as per the ESP template unless special requirements on product and process approval procedure should be defined by the Customer (e.g. Phased PPAP in accordance with AIAG). A set of initial sampling forms is to be found on the ESP for use in the verification process; they form the basis of the initial sampling documentation. Where the Supplier uses his own initial sampling documentation forms this will be permissible provided that their substance complies with the ESP template requirements.
AutoNDA by SimpleDocs
Initial sampling. ‌ Initial sample planning is to be prepared for the initial sampling run up to the sample test report. The nature and extent of initial sampling is defined during preliminary discussions with GG. All the features of the drawing and specification are to be verified on the initial samples. The parts from each nest are to be sampled for parts from multiple tools. The results need to be documented in the initial sample test report along with their actual and target values. Along with • the initial samples • the capability tests for features and characteristics key to quality • the Q planning documents (e.g. testing process plan, control plan) • the parts history • the material data sheet • and any other documents required by GG, the report needs to be presented to the Quality Dept. at GG. Initial sample deliveries are to be marked according to GG specifications. Deviations in the initial sample report are to be reconciled with the product development department responsible prior to the initial samples being presented and written approval obtained in the form of a deviation request. Series deliveries are only allowed to take place once GG has released the initial sample, and the design, materials and processes match the initial samples released. If further sampling is required, because the initial samples have been disposed of, the costs for this are to be covered by both Parties proportional to who incurs the costs. An initial sample being approved does not release the Supplier from its obligation and responsibility to deliver products free of defects. Responsibility for the quality of the product produced lies with the Supplier.
Initial sampling. (IATF 16949: Chapter 8.3.4.4) The initial sample documentation according to the required presentation levels (usually presentation level 3 or according to the customer's requirement) is to be delivered at the same time as the initial samples. Deficient or missing initial sample documentation can lead to a negative supplier evaluation. Initial samples without complete documentation will not be accepted and processed and may lead to subsequent costs which will be charged to the supplier. In the event of deviations, the SUPPLIER must obtain written approval from the Xxxx Group in advance and attach it to the submission. For initial orders of new products, the SUPPLIER shall provide samples for Europe in accordance with VDA Volume 2 (Production Process and Product Release PPF) and for NAFTA countries in accordance with AIAG PPAP, unless otherwise specified by the Xxxx Group. Alternatively, the sampling scope can also be agreed between the Xxxx Group and the SUPPLIER by means of a joint agreement. The initial sampling includes the use of the series tool, the series plant machines and devices. Compliance with the series parameters and cycle time at the series production site, series packaging and logistics must also be observed. Furthermore, initial sampling must be carried out by personnel who will also be used for further series production and who are trained in accordance with the work and test instructions. All required materials, products and processes must be approved. The SUPPLIER must record, document and archive the process parameters set during initial sampling and add them to the internal sampling documents. For all special characteristics and, if applicable, for further agreed test characteristics, the SUPPLIER must carry out and document detailed analyses of the suitability of the production facilities and test equipment used as well as process capability tests. For the determination of the machine capability MFU, all parts used must have the same prerequisites and be manufactured consecutively. For normal distributions, a sample of at least 50 pieces shall be selected.
Initial sampling. For initial samples, the supplier, upon request / order of the organization, will carry out an initial sample inspection to prove the required properties and submit the results together with the sample to theorganization for approval. All changes to this original manufacturing process must be notified to the organization in good time and approved by it. First sample parts are parts that have been manufactured entirely with standard equipment and under series conditions. These originate from a representative production process and must be explicitly marked as such.
Initial sampling. In principle Xxxxxx'x general terms of purchase provide for initial sampling for new phase-ins / changes of supplier in accordance with VDA for proof of quality of the supplier. XXXXXX is prepared and capable of providing XXXXXX, free of charge, proof of quality by means of initial sampling including initial sampling reports. The XXXXXX Initial Sampling Conditions shall apply (Appendix IV).
Initial sampling. Initial sampling takes place according to Bär’s specifications. This is always required before commencing with series production if:  a new component has been ordered  there has been a technical modification  a new tool, change/changeover of tool is required  the production site has been relocated  production has been suspended for an extended period (longer than 12 months)  this is instructed by Bär The initial samples must have been manufactured in full under series conditions. Any deviations from the planned status of the series manufacturing process shall be documented and agreed in writing with Bär in advance. After the initial samples have been presented, Bär shall carry out tests at its own discretion. Bär shall make his decision with regards to approval based on these measurement results and the ones provided by the Supplier. The Supplier is not released from his responsibility for the quality of the products if Bär approves the initial xxx- ple. The approval takes on a purely technical form and does not represent a delivery order. The Supplier shall supply the initial samples together with the requested initial sample test report. The tested components must be identified in such a way that assigning the measured values is straightforward. Delivery of series parts must only take place once the initial samples have been approved by Bär.
Initial sampling. Initial sample inspections are required in particular for Goods with Kärcher part numbers beginning with 1., 2., 3., 4., 5. or 8., and for those for which a corresponding note is included in the drawing or the external parts order form. Deviations from this will require agreement between the Supplier and the responsible purchaser of Kärcher. For series products, the Supplier is required to send Kärcher initial samples before the first series delivery of the relevant Goods and to submit an initial sample test report to Kärcher. Unless otherwise agreed or described in the order documents, the scope will comprise at least 30 sample parts for series products. The sample parts must come from a process that represents future series production in terms of manufacturing processes and manufacturing conditions. For the specific characteristics identified in the specifications, the Supplier will demonstrate the preliminary process capability with a sample size N ≥ 30. Unless otherwise specified, the target values for cp ≥ 1.33 and cpk ≥ 1.00 must be met (see also "Information sheet on initial sampling"). In the case of Goods which the Supplier purchases fully manufactured from subcontractors, the initial sample test report and samples may, in consultation between the Parties, also be submitted directly by the subcontractor. For repeat orders from Kärcher, a resubmission of production samples is generally not required. However, the Supplier must perform a new sampling if changes have occurred at the Supplier's premises as described in section 1.7 "Information requirements" of this QAA. See xxxxx://xxx.xxxxxxxx.xxx/int/inside-xxxxxxxx/company/supplier-area/download- area/company-standards/ahp_initial_sampling.html
AutoNDA by SimpleDocs
Initial sampling. New parts are to be supplied with an initial sample test report – either in compliance with VDA volume 2 Initial samples are to be manufactured with series-type equipment under production-line conditions. They have to comply with all specifications from drawings, technical guidelines, standards etc. Prior to the initial delivery, the supplier makes the EMPB audit report and sample parts available for approval testing. The required number of initial samples is usually 5 parts. The exact amount depends on the predetermined level. Sign-off of the initial samples does not release the supplier from the responsibility for the quality of their products. • Cover Sheet, Test Report • Control Plan, Test Plan • Process Capabilities (Cmk > 1,67 ; Cpk > 1,33) • Xxxxxxxx Xxxx Xxxxxxxxxxx XXX (XX 00000 „3.1“) • Drawing (poss. copy of the standard) with clear identification of all characteristics and specifications

Related to Initial sampling

  • Testing Landlord shall have the right to conduct annual tests of the Premises to determine whether any contamination of the Premises or the Project has occurred as a result of Tenant’s use. Tenant shall be required to pay the cost of such annual test of the Premises; provided, however, that if Tenant conducts its own tests of the Premises using third party contractors and test procedures acceptable to Landlord which tests are certified to Landlord, Landlord shall accept such tests in lieu of the annual tests to be paid for by Tenant. In addition, at any time, and from time to time, prior to the expiration or earlier termination of the Term, Landlord shall have the right to conduct appropriate tests of the Premises and the Project to determine if contamination has occurred as a result of Tenant’s use of the Premises. In connection with such testing, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such non-proprietary information concerning the use of Hazardous Materials in or about the Premises by Tenant or any Tenant Party. If contamination has occurred for which Tenant is liable under this Section 30, Tenant shall pay all costs to conduct such tests. If no such contamination is found, Landlord shall pay the costs of such tests (which shall not constitute an Operating Expense). Landlord shall provide Tenant with a copy of all third party, non-confidential reports and tests of the Premises made by or on behalf of Landlord during the Term without representation or warranty and subject to a confidentiality agreement. Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate any environmental conditions identified by such testing in accordance with all Environmental Requirements. Landlord’s receipt of or satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant.

  • Sampling The Licensee agrees that the Composition is purchased as a “Work Made for Hire” whereby the clearing of any sampled materials is the responsibility of Licensee.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Statistical Sampling Documentation a. A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.‌ b. A description or identification of the statistical sampling software package used by the IRO.‌

  • Feasibility Study A feasibility study will identify the potential costs, service quality and other benefits which would result from contracting out the work in question. The cost analysis for the feasibility study shall not include the Employer’s indirect overhead costs for existing salaries or wages and benefits for administrative staff or for rent, equipment, utilities, and materials, except to the extent that such costs are attributable solely to performing the services to be contracted out. Upon completion of the feasibility study, the Employer agrees to furnish the Union with a copy if the feasibility study, the bid from the Apparent Successful Bidder and all pertinent information upon which the Employer based its decision to contract out the work including, but not limited to, the total cost savings the Employer anticipates. The Employer shall not go forward with contracting out the work in question if more than sixty percent (60%) of any projected savings resulting from the contracting out are attributable to lower employee wage and benefit costs.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Bidder Supplied Samples The Commissioner reserves the right to request from the Bidder/Contractor a representative sample(s) of the Product offered at any time prior to or after award of a contract. Unless otherwise instructed, samples shall be furnished within the time specified in the request. Untimely submission of a sample may constitute grounds for rejection of Bid or cancellation of the Contract. Samples must be submitted free of charge and be accompanied by the Bidder’s name and address, any descriptive literature relating to the Product and a statement indicating how and where the sample is to be returned. Where applicable, samples must be properly labeled with the appropriate Bid or Contract reference. A sample may be held by the Commissioner during the entire term of the Contract and for a reasonable period thereafter for comparison with deliveries. At the conclusion of the holding period the sample, where feasible, will be returned as instructed by the Bidder, at the Bidder’s expense and risk. Where the Bidder has failed to fully instruct the Commissioner as to the return of the sample (i.e., mode and place of return, etc.) or refuses to bear the cost of its return, the sample shall become the sole property of the receiving entity at the conclusion of the holding period.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!